Arcadia Biosciences, Inc. · NASDAQ:RKDA
Arcadia Biosciences — Q3 2019 Earnings Presentation
7 slides from Arcadia Biosciences's earnings presentation, Nov 6, 2019
Slide 1: Q3 2019 Financial Results and Business Highlights
Q3 2019 Financial Results and Business Highlights Supplemental Slides November 6, 2019
Slide 2: Forward-looking statements
Forward-looking statements • “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This presentation contains forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success; the com
Slide 3: Well positioned for significant revenue generation based on 4 fundamentals
Well positioned for significant revenue generation based on 4 fundamentals Recent management guidance Initial revenues in 2019 Wheat; Hemp Total revenues for 2020 > $10.0 Million Total revenues for 2021 > $30.0 Million Positive net cash from Mid-to-late 2021 operations 1 2 2 3 Hemp Extraction Servic
Slide 4: Arcadia's product suite provides multiple opportunities to generate revenue each quarter
Arcadia’s product suite provides multiple opportunities to generate revenue each quarter 1Q 2Q 3Q 4Q Seeds Grain/ flour Traits/ royalty Seeds/ clones CBD, etc. Extraction services Traits SOY Seeds Purchase commitment Revenue recognition Estimates assume at
Slide 5: Hemp market expansion forecast to continue
Hemp market expansion forecast to continue Year over year growth in metrics U.S. acres planted Number of states with pilot programs 250000 40 35 187% 200000 average 30 yearly 25 150000 growth 20 100000 15 10 50000 5 0 0 2016 2017 2018 2019 2016 2017 2018 2019 Source: Vote Hemp www.votehemp.com 11/06
Slide 6: Hemp-derived CBD is increasingly seen as a medication alternative and desirable ingredient
Hemp-derived CBD is increasingly seen as a medication alternative and desirable ingredient in food & cosmetics Who uses CBD? How old are they? Major companies selling CBD products of Americans have tried CBD at least once in the past two years Companies using CBD as an ingredient Source: Consumer Re
Slide 7: Key financial results
Key financial results Third Quarter First Nine Months Favorable/(Unfavorable) Favorable/(Unfavorable) 2019 2018 $ % 2019 2018 $ % Total revenues 392 370 22 6% 753 1,020 (267) (26%) Cost of product revenues 177 124 (53) (43%) 324 431 107 25% R&D expense 1,931 1,334 (597) (45%) 5,387 4,524 (863) (19%)